BioMerieux to Move Array-Based Tests to Biocartis, Other MDx Platforms

BioMerieux, an Affymetrix diagnostics partner, will use the Affy platform for R&D, but "not for tests that we commercialize."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.